
O. Joe Hines, MD, FACS, is Professor and Chair of the Department of Surgery at UCLA, Executive Medical Director, and William P. Longmire, Jr., Chair in Surgery.
Dr. Hines attended the University of Oklahoma College of Medicine and was inducted into Alpha Omega Alpha Honor Society. He trained in general surgery at UCLA, including two years of research in gastrointestinal physiology, and was then recruited to the UCLA faculty in 1997. While at UCLA, he has received the Department Golden Scalpel Award for teaching excellence and the UCLA School of Medicine Award for Excellence in Education and the David Geffen School of Medicine at UCLA, Sherman M. Mellinkoff Faculty Award.
His research has focused on angiogenesis, cytokines, and pancreatic carcinogenesis, including the role of diet in modulating these processes. Dr. Hines’ research has been consistently funded by NIH, and he has served on the NIH Scientific Review Committee Tumor Progression and Metastasis.
Dr. Hines is past-President of the American Pancreatic Association and the Chair of the American Pancreatic Association Foundation. He served as Chair of the American Board of Surgery, President of the Society of University Surgeons, President of the Southern California Chapter of the American College of Surgeons and was appointed to the Board of Governors of the American College of Surgeons. Dr. Hines was awarded the American College of Surgeons Traveling Fellowship to Germany in 2005 and was a James IV Traveling Fellow in 2011. He serves on the editorial boards of Surgery and Annals of Surgery and is an editor of Maignot’s Abdominal Operations.
Selected publications from PubMed
Riesz Representers for the Rest of Us.
Williams NT, Hines OJ, Rudolph KE
Epidemiology. 2026 Sep 1;37(5):596-602 doi: 10.1097/EDE.0000000000001996.
The Principles of Inclusive Excellence are Important to the Surgeon's Mission.
Jimenez JC, Rowe VL, McIntosh D, Hines OJ
Ann Surg Open. 2026 Jun;7(2):e662 doi: 10.1097/AS9.0000000000000662.
Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity score-matched analysis.
Shimizu T, Zheng S, Maeda S, Link J, Deranteriassian A, Premji A, King J, Girgis M, Hines OJ, Wainberg Z, Raldow A, He J, Burns W, Narang A, Qadan M, Castillo CF, Lillemoe KD, Wo J, Hong T, Donahue TR
J Gastrointest Surg. 2026 Apr;30(4):102358 doi: 10.1016/j.gassur.2026.102358.
Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
Wainberg ZA, Link JM, Premji A, Zheng S, Srienc M, Hammons M, Kim SE, Li L, Liu Z, Tsvetkova O, Abt ER, Rosen L, Kim S, King J, Hines OJ, Girgis M, Sadeghi S, Olevsky O, Wong D, Yonemoto L, Siney AM, Kelly K, Kivork C, Tseng CH, Radu CG, Dawson DW, Donahue TR
Nat Commun. 2026 Jan 31;17(1) doi: 10.1038/s41467-026-68976-2.
Variable importance measures for heterogeneous treatment effects.
Hines OJ, Diaz-Ordaz K, Vansteelandt S
Biometrics. 2025 Oct 8;81(4) doi: 10.1093/biomtc/ujaf140.
Help your network discover Dr. O. Joe Hines's clinical expertise.